bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer in Cambridge, Massachusetts and Seattle, Washington.
BLUE’s product candidates include Lenti-D that is in phase II/III clinical studies for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in four clinical studies for the treatment of transfusion-dependent ß-thalassemia, and severe sickle cell disease. The company's lead product candidate in oncology is bb2121, a chimeric antigen receptor T cell product candidate that is in a Phase I trial for the treatment of relapsed/refractory multiple myeloma.
BLUE has a strategic collaborations with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; and Kite Pharma (now Gilead). to develop and commercialize second generation T cell receptor (TCR) product candidates against an antigen related to certain cancers associated with the human papilloma virus. It also has strategic collaborations with Medigene AG for the research and development of TCR product candidates directed against approximately four antigens for the treatment of cancer indications; and TC BioPharm to research and develop gamma delta CAR T cell product candidates for cancer immunotherapy.
BLUE was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.
April 13, 2015
RegMed dipped in and out of negative territory shifting to the upside
April 13, 2015
RegMed mid-day: reset with palpable moves
April 12, 2015
RegMed’s snap, crackle and pop
April 10, 2015
RegMed mid-day: low volume displays pricing strength
April 9, 2015
RegMed: share pricing traffic is impede by directionless signals
April 9, 2015
Lower open expected, RegMed direction and digestion
April 8, 2015
RegMed: the downside of strength - volume
April 8, 2015
Higher open expected, RegMed waits for the shoe to drop
April 7, 2015
RegMed; fast and furious 2, loving the ride but, needs to find an exit for gas
April 7, 2015
RegMed: fast and furious
35 companies, 1 interpreter!
Insight, foresight and recommendation
bluebird Bio (BLUE) – BLUE has been on a tear since 8/21/17 with some dips as January opened at $181.90 with a 1/9 low of $169.50; jumping 2/1 to $205.25 slipping to $191.50 on 2/09 with a pricing of $213.25 on 2/16 ... WHO can argue with this momentum. Celgene's (CELG) option and ownership is a solid foundation ... yet, why any buy-out at this price? It will dip, slip and return but, ebb over time ... yet worth "playing" the pains and gains
sellMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.